BRISTOL-MYERS SQUIBB COMPANY Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $239.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for the quarter ending 2019-09-30 was $81.00M, a 65.31% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for the quarter ending 2018-09-30 was $49.00M.
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2025 was $239.00M, a 7866.67% increase from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $3.00M, a 25.00% decline from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $4.00M, a 95.18% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $83.00M, a 1560.00% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 3 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | $239.00M 10-K · filed 2026-02-11 | ||
| 2024-12-31 | $3.00M 10-K · filed 2026-02-11 | ||
| 2023-12-31 | $4.00M 10-K · filed 2026-02-11 | ||
| 2022-12-31 | $83.00M 10-K · filed 2025-02-12 | ||
| 2021-12-31 | $5.00M 10-K · filed 2024-02-13 | ||
| 2020-12-31 | $5.00M 10-K · filed 2023-02-14 | ||
| 2019-12-31 | $72.00M 10-K · filed 2022-02-09 | ||
| 2019-09-30 | $81.00M 10-Q · filed 2020-11-05 | ||
| 2018-12-31 | $119.00M 10-K · filed 2021-02-10 | ||
| 2018-09-30 | $49.00M 10-Q · filed 2019-10-31 | ||
| 2017-12-31 | $13.00M 10-K · filed 2020-02-24 | ||
| 2016-12-31 | $4.00M 10-K · filed 2019-02-25 | ||
| 2015-12-31 | $9.00M 10-K · filed 2018-02-13 | ||
| 2014-12-31 | $12.00M 10-K · filed 2017-02-21 | ||
| 2013-12-31 | $8.00M 10-K · filed 2016-02-12 | ||
| 2012-12-31 | $19.00M 10-K · filed 2015-02-13 | ||
| 2011-12-31 | $7.00M 10-K · filed 2014-02-14 | -$7.00M 10-K · filed 2012-02-17 | |
| 2010-12-31 | $7.00M 10-K · filed 2013-02-15 | -$7.00M 10-K · filed 2011-02-18 | |
| 2009-12-31 | -$29.00M 10-K · filed 2012-02-17 | ||
| 2008-12-31 | -$378.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |